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Wakayama, Kyoto, Osaka, Hiroshima, Mie, Kumamoto, Matsue, Kochi, Komatsushima, Kurashiki,
Sapporo, Tokyo, and Ogaki, JapanObjectives This study assessed 5-year outcomes after implantation of sirolimus-eluting stents (SES) for
unprotected leftmain coronary artery (ULMCA) disease in comparisonwith that for non-leftmain disease.
Background More information on long-term outcomes after ULMCA stenting is needed.
Methods The j-Cypher is a multicenter prospective registry of consecutive patients undergoing SES
implantation in Japan.
Results Among 12,812 patients enrolled in the j-Cypher registry, the unadjusted mortality rate at
5 years was signiﬁcantly higher in patients with ULMCA stenting than in patients without ULMCA
stenting (22.8% vs. 14.1%; p < 0.0001); however, the risk for death with ULMCA stenting was no longer
signiﬁcant after adjusting for confounders (hazard ratio: 1.18, 95% conﬁdence interval: 0.95 to 1.46;
p ¼ 0.14). In the lesion-level comparison, the nonbifurcation ULMCA lesions treated exclusively with
SES had a signiﬁcantly lower rate of target lesion revascularization (TLR) than those in non-ULMCA
nonbifurcation lesions (2.4% vs. 12.7%; p ¼ 0.04). Among bifurcation lesions, those treated with
a provisional 2-stent approach had similar rates of TLR (12.1% vs. 11.4%; p ¼ 0.79) between the ULMCA
and non-ULMCA groups. Lesions treated with an elective 2-stent approach had higher TLR rates in the
ULMCA group as compared with the non-ULMCA group (33.5% vs. 19.7%; p ¼ 0.002).
Conclusions The safety of ULMCA stenting relative to non-LMCA stenting was maintained through
5 years follow-up. In terms of efﬁcacy, SES implantation in nonbifurcation ULMCA lesions was
associated with an extremely low cumulative incidence of TLR, whereas the elective 2-stent approach
for ULMCA bifurcation lesions was associated with a markedly higher cumulative incidence of TLR as
compared with that for non-ULMCA bifurcation lesions. (J Am Coll Cardiol Intv 2013;6:654–63)
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655Current guidelines allow percutaneous coronary intervention (non-ULMCA group). Lesion-based analysis was also con-Abbreviations
and Acronyms
CABG = coronary artery(PCI) for unprotected left main coronary disease (ULMCA)
in limited situations (1,2). However, appropriate indications
for PCI in patients with ULMCA are still unclear, and more
information on long-term outcomes after ULMCA stenting
is needed.
Our previous report from the j-Cypher registry at 3 years
suggested: 1) percutaneous treatment for left main disease
was safe, with a similar adjusted mortality rate as compared
with the treatment for non-left main disease through 3
years; and 2) there is heterogeneity of outcomes between
left main lesion locations (ostial/shaft and bifurcation) and
bifurcation stenting strategies (bifurcation 1-stent and
2-stent strategies) (3).
In the current report, we assessed the longer-term safety
and efﬁcacy of ULMCA PCI relative to non-ULMCA PCI
through 5 years in the j-Cypher registry cohort. The
subgroup analysis comparing the outcomes of ULMCA
lesions with those of non-ULMCA lesions was also con-
ducted according to lesion locations and bifurcation stenting
strategies to assess the issues speciﬁc for left main lesions.bypass grafting
CI = conﬁdence interval
HR = hazard ratio
LCX = left circumﬂex
coronary artery
MI = myocardial infarction
PCI = percutaneous coronary
intervention
SES = sirolimus-eluting
stent(s)
ST = stent thrombosis
TLR = target-lesion
revascularization
ULMCA = unprotected left
main coronary arteryMethods
Study design and patient population. The study design and
patient enrollment for the j-Cypher registry have already
been described in detail (4). In brief, the j-Cypher registry
is a physician-directed, prospective, multicenter registry in
Japan enrolling consecutive patients undergoing sirolimus-
eluting stent (SES) implantation. From August 2004 to
November 2006, 12,824 patients were enrolled in the
j-Cypher registry for the ﬁrst time. Excluding 2 patients
without successfully treated lesions, 4 patients without stent
use, and patients with bare-metal stent use only, the current
study population consists of 12,812 patients treated with at
least 1 SES. The recommended antiplatelet regimens were
indeﬁnite use of aspirin (81 to 100 mg/day) and a thieno-
pyridine (200 mg of ticlopidine or 75 mg of clopidogrel
daily) for at least 3 months. The duration of dual-antiplatelet
therapy was left to the discretion of each attending physi-
cian. The relevant review boards in all 37 participating
centers approved the study protocol. Written informed
consent was obtained from all patients enrolled.
Among 12,812 study patients, 582 patients underwent
PCI for ULMCA disease (ULMCA group), and 12,230
patients underwent PCI only for non-ULMCA lesionssupported by Cordis Cardiology Japan and Johnson & Johnson. Dr. Kimura has served
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accepted March 28, 2013.ducted in 476 ULMCA lesions treated exclusively by SES
in comparison with 14,898 non-ULMCA lesions treated
similarly (Fig. 1). Lesions were divided into 3 groups in-
cluding nonbifurcation lesions, bifurcation lesions treated
with a provisional 2-stent approach, and bifurcation lesions
treated with an elective 2-stent approach. In an attempt to
select the lesions comparable with the ULMCA lesions, the
following lesions were excluded from the control group: non-
SES treatment, treatment with both SES and other drug-
eluting stents, protected left main lesions, bifurcation lesion
morphology without proximal main branch disease (Medina
class 0.1.0, 0.0.1, 0.1.1), and unsuccessfully treated lesions.
Deﬁnitions. The left main coronary artery was deﬁned as
“unprotected” when no surgical grafts to the left coronary
system were patent. Renal failure was deﬁned as an esti-
mated glomerular ﬁltration rate <30 ml/min/1.73 m2.
Coronary angiographic parame-
ters were assessed in each partici-
pating center by either visual
assessment or quantitative angio-
graphicmeasurement. Bifurcation
lesion was deﬁned as a lesion
involving a side branch 2.2 mm
in diameter that could be a candi-
date for stent implantation.When
stenting was performed for the
side-branch ostium (left circum-
ﬂex [LCX] in the vast majority
of the ULMCA cases]) before
stenting of the main branch, the
procedure was regarded as an elec-
tive 2-stent strategy. The provi-
sional 2-stent strategy was deﬁned
as either main branch stenting
alone or stenting for the side-
branch ostium after stenting of the
main branch. Bifurcation 2-stent treatment was deﬁned as
stenting of both the main and side branches, and 1-stent
treatment as stenting of the main branch alone. The decision
for performing a ﬁnal kissing balloon dilation was also left to
the operators. During the follow-up, death was regarded as
cardiac in origin unless obvious noncardiac causes were
identiﬁed. Any death during the index hospitalization for
stent implantation was regarded as cardiac death. Myocardial
infarction (MI) was adjudicated according to the deﬁnition in
the Arterial Revascularization Therapy Study (5). Stent
thrombosis (ST) was deﬁned according to the Academic
Research Consortium (ARC) deﬁnition (6). Target-lesion
revascularization (TLR)was deﬁned as either PCI or coronary
artery bypass graft surgery due to restenosis or thrombosis of
the target lesion that included the proximal and distal edge
segments and the ostium of side branches. A scoring system
used in the SYNTAX (Synergy Between Percutaneous
Figure 1. Patient Flowchart
Among the study patients, 582 patients underwent percutaneous coronary intervention (PCI) for unprotected left main coronary artery (ULMCA) disease.
BMS ¼ bare-metal stents; DES ¼ drug-eluting stents; SES ¼ sirolimus-eluting stents.
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trial (SYNTAX score) was calculated to evaluate the anatomic
complexity, and the tertile ranges in the original SYNTAX
trial (7) were used in the post hoc analysis.
The primary outcome measure for the current analysis was
all-cause death through 5 years after the index procedures.
Cardiac death, MI, ST, and repeated revascularization were
also assessed on a patient-level basis. TLR and ARC deﬁnite
ST were evaluated on a lesion-level basis as subgroup analyses
according to the lesion location and stenting strategies.
Statistical analysis. Categorical variables are presented as
counts and/or percentages and were compared with the chi-
square test. Continuous variables were expressed as mean 
SD or median and interquartile ranges. Continuous variables
were compared with the Student t test, analysis of variance,
or Wilcoxon rank sum test on the basis of their distributions.
Cumulative incidences of adverse events were estimated by
the Kaplan-Meier method, and curves were compared with
the log-rank test. We used the Cox proportional hazard
model to make adjusted comparison for death and cardiac
death. All variables in Table 1 were used as potential risk-
adjusting variables dichotomized by clinically meaningful
thresholds and used as potential risk-adjusting variables, and
we selected those variables with a univariate p value <0.05
for the multivariable model (Online Table 1, Model 1). As
a sensitivity analysis to identify the fair combination of the
explanatory variables, a backward variable selection on the
multivariable Cox proportional hazard model with all
selected factors was conducted and identiﬁed the indepen-
dent explanatory variables with a p value <0.05 (OnlineTable 1, Model 2). Adjusted survival curves were drawn for
the 2 groups of patients with or without ULMCA stenting
by use of the Cox proportional hazard model in conjunction
with methods described by Ghali et al. (8) with adjustment
for the aforementioned variables.
On an assumption with proportional hazard by the plot of
log (time) versus log [log (survival)] stratiﬁed by inde-
pendent variables, multivariable Cox proportional hazard
models for TLR were developed within the ﬁrst year and
beyond 1 year separately, with previously identiﬁed inde-
pendent risk factors consistent with our prior report (9). In
evaluating risk factors for TLR beyond 1 year, we included
only those patients who completed the 1-year follow-up
without TLR.
Probability was considered to be signiﬁcant at a level of
<0.05. All statistical tests were 2-tailed. Statistical analyses
were conducted by a physician (M.T.) and by an indepen-
dent statistician (T.M.) with the use of JMP version 8.0.2
(SAS Institute, Cary, North Carolina), and SAS version 9.2
(SAS Institute) software.Results
Baseline and procedural characteristics. Patients in the
ULMCA group were signiﬁcantly older and had more
comorbidities than those in the non-ULMCA group, as
reﬂected by the higher incidences of stroke, heart failure,
renal failure, unstable angina, shock, and bifurcation disease
(Table 1).
Table 1. Baseline Characteristics of Patients According to
Stenting for ULMCA
ULMCA
(n ¼ 582)
Non-ULMCA
(n ¼ 12,230) p Value
Age, yrs 70.7  10.6 68.3  10.2 <0.0001
Age 75 yrs 39.5 29.9 <0.0001
Male 72.7 75.4 0.14
Emergent procedure 20.5 14.8 0.0004
Presence of shock 3.4 1.3 0.0001
Presence of STEMI 7.4 9.8 0.053
Acute coronary syndrome 30.9 24.5 0.0007
Hypertension 73.5 74.6 0.56
Diabetes 42.6 41.4 0.58
Diabetes, insulin 12.0 9.3 0.029
Current smoking 15.1 20.6 0.001
Dyslipidemia, treated 43.8 44.6 0.73
Serum creatinine, mg/dl 0.91 (0.79–1.15) 0.90 (0.75–1.10) 0.0006
Estimated GFR,
ml/min/1.73 mm2
55  24 59  23 <0.0001
Renal failure 15.3 9.9 <0.0001
Dialysis 7.4 5.2 0.03
LVEF, % 56  15 58  13 0.0008
Heart failure 24.1 13.5 <0.0001
EuroScore 5.8  3.6 4.6  3.1 <0.0001
EuroScore 6 46.6 33.1 <0.0001
Bifurcation lesion 81.4 24.0 <0.0001
Bifurcation 2 stenting 29.6 4.6 <0.0001
Treated vessel, n 1.9  0.8 1.3  0.5 <0.0001
Prior PCI 43.3 46.6 0.13
Prior CABG 7.9 7.1 0.46
Prior MI 25.1 27.3 0.25
History of stroke 13.2 9.3 0.003
Extracardiac arteriopathy 13.4 11.8 0.24
Extent of coronary artery
disease
Left main only 6.9
1 Vessel 23.9 47.1
2 Vessel 40.0 29.7
3 Vessel 21.3 14.3
Post-CABG 7.9 6.8
Total stent length, mm 56  37 42  27 <0.0001
Implanted stents, n 2.6  1.6 1.9  1.2 <0.0001
IVUS use 63.4 46.8 <0.0001
Aspirin use 98.9 98.7 0.84
Ticlopidine use 95.7 96.4 0.11
Clopidogrel use 4.5 2.3 0.01
Cilostazol use 4.9 3.2 0.03
ACE-I use 19.7 17.0 0.1
ARB use 35.7 37.6 0.4
Beta-blocker use 25.5 28.4 0.15
Statins use 52.1 48.7 0.12
Values are %, mean  SD, or median (interquartile range).
ACE-I ¼ angiotensin converting enzyme inhibitor; ACS ¼ acute coronary syndrome; ARB ¼
angiotensin type II receptor blocker; CABG ¼ coronary artery bypass grafting; GFR¼ glomerular
ﬁltration rate; IVUS ¼ intravascular ultrasound; LVEF ¼ left ventricular ejection fraction; MI ¼
myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment eleva-
tion myocardial infarction; ULMCA ¼ unprotected left main coronary artery.
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657Outcomes of patients with or without ULMCA stenting. The
cumulative incidences of all-cause death and cardiac death
up to 5 years were signiﬁcantly higher in patients with
ULMCA disease (Table 2, Fig. 2A). After adjusting for
confounders, there were no signiﬁcant differences in the risk
for all-cause death and cardiac death between the ULMCA
group and the non-ULMCA group (hazard ratio [HR]:
1.18, 95% conﬁdence interval [CI]: 0.95 to 1.46; p ¼ 0.14,
and HR: 1.01, 95% CI: 0.72 to 1.41; p ¼ 0.97, respectively)
(Fig. 2B, Online Table 1, Model 1) As a sensitivity analysis,
we conducted a backward-selection procedure on the mul-
tivariable Cox proportional hazard model with all selected
risk factors, and the model yielded a similar result for all-
cause death (HR: 1.18, 95% CI: 0.95 to 1.47; p ¼ 0.13)
(Online Table 1, Model 2).
Distributions of the causes of death were comparable
between patients with and without ULMCA treatment
(Online Table 2). There was no excess of patients who died
from documented ventricular ﬁbrillation and/or patients
with sudden death in the ULMCA group.
The cumulative incidences of ST (both deﬁnite and
deﬁnite/probable) were marginally higher in the ULMCA
group as compared with the non-ULMCA group in the
patient-level analysis (Table 2); however, the cumulative
incidences of deﬁnite ST in the lesion-level analysis were not
signiﬁcantly different between the ULMCA and non-
ULMCA groups (1.7% vs. 1.1%; p ¼ 0.38). The cumulative
incidences of TLR at the patient level were signiﬁcantly
higher in the ULMCA group than that in the non-
ULMCA group (22.6% vs. 17.3%; p < 0.0001); however,
the difference between the 2 groups was attenuated at the
lesion level (15.2% vs. 13.6%; p ¼ 0.051). The cumulative
incidences of MI, stroke, and any repeated revascularization
in the patient-level analysis were similar between the
ULMCA and non-ULMCA groups (Table 2).
Clinical outcomes among nonbifurcation lesions. Among
476 ULMCA lesions treated exclusively with SES, 96 (20%)
had ostial/shaft left main lesions and were compared with
13,249 nonbifurcation non-ULMCA lesions. With regard
to lesion and procedural characteristics, ULMCA lesions
had more severe calciﬁcation, more frequent IVUS guidance,
shorter stent length, larger stent diameter, and higher
maximal balloon inﬂation pressure (Table 3). Clinical
outcomes at 5 years were remarkably more favorable in
the ULMCA group than in the non-ULMCA group
(deﬁnite ST: 0% vs. 1.2%; p ¼ 0.35, and TLR: 2.4% vs.
12.7%; p ¼ 0.04) (Table 4, Fig. 3). After adjusting for
confounders, the lower risk for TLR in the ULMCA group
was marginal (HR for early TLR within 1 year 0.27, 95%
CI: 0.02 to 1.21; p ¼ 0.1, and beyond 1 year, HR: 0.46, 95%
CI: 0.07 to 1.43; p ¼ 0.21).
Clinical outcomes among bifurcation lesions treated with
the provisional 2-stent approach. Among 380 ULMCA
bifurcation lesions, 281 lesions (74%) were treated with the
Table 2. Unadjusted Event Rates After Index PCI According to the
Treatment for ULMCA Through 5 Years
ULMCA
(n ¼ 582)
Non-ULMCA
(n ¼ 12,230) p Value*
Total death 110 (22.8) 1,435 (14.0) <0.0001
Cardiac death 52 (11.2) 675 (6.7) <0.0001
Sudden death 14 (3.4) 234 (2.4) 0.19
MI 22 (5.6) 366 (3.7) 0.19
Stroke 31 (6.9) 573 (5.8) 0.11
Deﬁnite ST, patient level 12 (2.7) 162 (1.6) 0.1
Deﬁnite ST, lesion level 7 (1.7) 170 (1.1) 0.38
Deﬁnite/probable ST 15 (3.2) 199 (2.1) 0.04
Any ST 31 (7.2) 514 (5.3) 0.07
TLR, patient level 111 (22.6) 1,796 (17.3) <0.0001
TLR, lesion level 76 (15.2) 2,166 (13.6) 0.051
CABG 10 (2.2) 258 (2.7) 0.71
Any revascularization 195 (39.6) 4,087 (38.5) 0.14
Values are the crude event n (event rates estimated by Kaplan-Meier method). *The p values
are for the comparison between the ULMCA group and non-ULMCA group at 5 years after the
index coronary intervention using the log-rank test.
ST ¼ stent thrombosis; TLR ¼ target lesion revascularization; other abbreviations as in
Table 1.
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658provisional 2-stent approach, whereas 99 lesions (26%) were
treated with the elective 2-stent approach. Crossover to ﬁnal
2-stent treatment occurred in 20 lesions (7%) of 281 lesions
with the provisional 2-stent approach. Among bifurcation
lesions with the provisional 2-stent approach, the ULMCA
group (281 lesions) as compared with the non-ULMCA
group (1,433 lesions) had a higher prevalence of heartFigure 2. Unadjusted and Adjusted Survival Rates in Patients With or Without U
The cumulative incidences of all-cause death up to 5 years were signiﬁcantly higher
for confounders, there were no signiﬁcant differences in the risk for all-cause death
in Figure 1.failure, renal failure, and more severe calciﬁcations (Table 3).
There were more frequent IVUS guidance, shorter stent
length, larger stent diameter, higher balloon inﬂation pres-
sure, and more frequent ﬁnal kissing balloon inﬂation in the
ULMCA lesions. The cumulative incidence of deﬁnite ST
at 5 years was low in both the ULMCA and non-ULMCA
bifurcation lesions treated with the provisional 2-stent
approach (1.2% vs. 1.4%; p ¼ 0.62) (Table 4, Fig. 4). The
cumulative incidence of TLR was comparable between the
ULMCA and non-ULMCA groups (12.1% vs. 11.4%; p ¼
0.79). The risk of the ULMCA lesions for TLR remained
insigniﬁcant after adjusting for confounders (HR for early
TLR within 1 year 1.45, 95% CI: 0.78 to 2.52; p ¼ 0.23,
and beyond 1 year, HR: 1.12, 95% CI: 0.59 to 1.98;
p ¼ 0.71).
Clinical outcomes among bifurcation lesions treated with
elective 2-stent approach. Among 316 bifurcation lesions
treated with the elective 2-stent approach (ULMCA 99
lesions, and non-ULMCA 217 lesions), renal failure, dial-
ysis, and severe calciﬁcation were more prevalent in the
ULMCA group than in the non-ULMCA group (Table 3).
Stent diameters were larger in both main and side branches,
and ﬁnal kissing balloon inﬂation was more frequently
conducted in the ULMCA group as compared with non-
ULMCA group. The cumulative incidence of TLR through
5 years was signiﬁcantly higher in the ULMCA group as
compared with the non-ULMCA group (33.5% vs. 19.7%;
p ¼ 0.002) (Table 4, Fig. 5). After adjusting for
confounders, the higher risk of ULMCA lesions for early
TLR was signiﬁcant (HR for TLR within 1 year 2.88, 95%LMCA Stenting
in patients with ULMCA disease (unadjusted survival rates) (A). After adjusting
between the ULMCA group and the non-ULMCA group (B). Abbreviations as
Table 3. Lesion and Procedure Characteristics According to Treatment for ULMCA at the Lesion Level
Nonbifurcation Provisional 2-Stent Elective 2-Stent
ULMCA
(n ¼ 96)
Non-ULMCA
(n ¼ 13,249) p Value
ULMCA
(n ¼ 281)
Non-ULMCA
(n ¼ 1,433) p Value
ULMCA
(n ¼ 99)
Non-ULMCA
(n ¼ 217) p Value
Diabetes 43.8 43.1 0.92 38.4 38.1 0.38 50.5 45.2 0.40
Heart failure 18.8 9.9 0.0089 18.2 8.3 <0.0001 15.2 8.3 0.08
Renal failure 14.6 10.8 0.24 12.8 8.1 0.016 22.2 11.5 0.02
Dialysis 7.3 5.5 0.37 5.3 3.8 0.24 15.2 6.5 0.02
De novo lesion 83.3 75.7 0.094 79.0 77.7 0.69 77.8 76.7 0.58
ISR lesion 11.5 12.1 1.00 7.8 11.1 0.11 13.1 7.8 0.15
Calciﬁcation, severe 4.2 8.5 0.19 12.1 7.3 0.012 22.2 8.8 0.002
IVUS guidance 60.6 42.4 0.0005 66.9 45.9 <0.0001 59.6 50.0 0.11
Total stent length per lesion, MB, mm 16.6  6.8 28.1  15.0 <0.0001 25.4  11.6 30.5  14.9 <0.0001 42.0  12.8 44.2  18.8 0.30
Nominal stent diameter, MB, mm 3.3  0.3 2.9  0.4 <0.0001 3.26  0.29 2.87  0.32 <0.0001 3.10  0.3 2.81  0.28 <0.0001
Total stent length per lesion, SB, mm 19.3  4.6 19.8  3.1 0.55 20.1  5.8 21.9  7.2 0.03
Nominal stent diameter, SB, mm 2.9  0.3 2.6  0.2 <0.0001 2.9  0.4 2.6  0.2 <0.0001
Max balloon pressure, atm 20.0  3.0 18.0  3.4 <0.0001 18.9  3.2 17.6  3.4 <0.0001 18.6  3.1 17.6  3.1 0.01
Lesion morphology
Medina 1.0.0 22.3 13.5 <0.0001 2.0 5.1 0.19
Medina 1.1.0 37.1 29.5 8.0 7.8
Medina 1.1.1 30.6 48.0 74.8 78.8
Medina 1.0.1 10.1 9.0 15.2 8.3
SB angulation 70 44.4 11.6 <0.0001 42.9 11.6 <0.0001
Final KBT 75.8 53.0 <0.0001 93.9 84.8 0.03
SB stenting 7.1 4.6 0.098 100 100
Bifurcation technique
T-stenting 65.0 81.8 0.25 54.6 49.8 0.03
Crush stenting 15.1 29.0
Culotte stenting 30.0 16.7 26.3 16.1
Kissing stenting 5.0 1.5 4.0 5.1
Follow-up angiography 78.1 74.4 0.48 75.4 75.6 1.0 65.7 75.0 0.058
Values are percent or mean  SD.
ISR ¼ in-stent restenosis; KBT ¼ kissing balloon technique; MB ¼ main branch; SB ¼ side branch; other abbreviations as in Table 1.
Table 4. Cumulative Incidence of Events After Index PCI According to Treatment for ULMCA at the Lesion Level
Nonbifurcation Provisional 2-Stent Elective 2-Stent
ULMCA
(n ¼ 96
Non-ULMCA
(n ¼ 13,249) p Value*
ULMCA
(n ¼ 281)
Non-ULMCA
(n ¼ 1,433) p Value*
ULMCA
(n ¼ 99)
Non-ULMCA
(n ¼ 217) p Value
30 days
ST 0 36 (0.3) 0 5 (0.3) 1 (1.1) 0
TLR 0 49 (0.4) 2 (0.7) 5 (0.3) 2 (2.1) 0
1 year
ST 0 52 (0.4) 1 (0.4) 6 (0.4) 3 (3.4) 3 (1.5)
TLR 1 (1.1) 670 (5.1) 15 (5.5) 67 (4.8) 26 (28.8) 24 (12.5)
5 years
ST 0 126 (1.2) 0.35 2 (1.2) 15 (1.4) 0.62 3 (3.4) 4 (2.3) 0.44
TLR 2 (2.4) 1,386 (12.7) 0.038 28 (12.1) 135 (11.4) 0.79 30 (33.5) 37 (19.7) 0.002
Values are crude event n (event rates estimated by Kaplan-Meier method). *The p values are for the comparison between the ULMCA group and non-ULMCA group at 5 years after the index coronary
intervention using the log-rank test.
Abbreviations as in Tables 1 and 2.
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Figure 3. Kaplan-Meier Curves for Cumulative Incidences of TLR and Deﬁnite ST Among Nonbifurcation Lesions: ULMCA Versus Non-ULMCA Lesions
Target lesion revascularization (TLR) (A) and deﬁnite stent thrombosis (ST) (B) among nonbifurcation lesions. Among nonbifurcation lesions, clinical outcomes at
5 years were remarkably more favorable in the ULMCA group than in the non-ULMCA group. Abbreviations as in Figure 1.
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660CI: 1.54 to 5.44; p ¼ 0.001, and HR for TLR beyond 1 year
0.61, 95% CI: 0.17 to 1.79; p ¼ 0.38). Among bifurcation
lesions, the interaction probability between ULMCA
treatment and the elective 2-stenting for early TLR within 1
year was 0.03. The cumulative incidence of deﬁnite ST was
comparable between the ULMCA and non-ULMCA
groups (3.4% vs. 2.3%; p ¼ 0.44).Figure 4. Kaplan-Meier Curves for Cumulative Incidences of TLR and Deﬁnite ST
2-Stenting Approach: ULMCA Versus Non-ULMCA Lesions
The cumulative incidences of TLR (A) and deﬁnite ST (B) were comparable between th
approach. Abbreviations as in Figures 1 and 3.Cumulative 5-year incidences of deﬁnite ST and TLR in
lesions managed with bifurcation 1-stent treatment were
similar between the ULMCA and non-ULMCA groups
(deﬁnite ST: 1.4% vs. 1.4%; p ¼ 0.72, and TLR: 12.3% vs.
11.0%; p ¼ 0.67, respectively). In lesions managed with the
bifurcation 2-stent treatment of both branches, the cumu-
lative incidence of deﬁnite ST was similar between theAmong Bifurcation Lesions Treated With the Provisional
e ULMCA and non-ULMCA bifurcation lesions treated with the provisional 2-stent
Figure 5. Kaplan-Meier Curves for Cumulative Incidences of TLR and Deﬁnite ST Among Bifurcation Lesions Treated With the Elective
2-Stenting Approach: ULMCA Versus Non-ULMCA Lesions
The cumulative incidence of TLR (A) through 5 years was signiﬁcantly higher in the ULMCA group as compared with the non-ULMCA group. (B) The cumulative
incidence of deﬁnite ST in the ULMCA group as compared with the non-ULMCA group is shown. Abbreviations as in Figures 1 and 3.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 7 , 2 0 1 3 Toyofuku et al.
J U L Y 2 0 1 3 : 6 5 4 – 6 3 Five Year Outcomes After SES Implantation in ULMCA Disease
661ULMCA and non-ULMCA groups (2.8% vs. 2.1%; p ¼
0.56), whereas the cumulative incidence of TLR was
signiﬁcantly higher in the ULMCA group than in the non-
ULMCA group (29.6% vs.19.7%; p ¼ 0.007).
Risk stratiﬁcation among patients treated for ULMCA. Among
476 patients treated for ULMCA exclusively with SES, the
cumulative incidences of death, cardiac death, sudden death,
and MI through 5 years were comparable among the 3
groups of nonbifurcation, bifurcation provisional 2-stent
approach, and elective 2-stent approach (Table 5). The
cumulative incidence of TLR was low in the nonbifurcation
lesion, and high in bifurcation elective 2-stent treatment, as
described in the previous text. The rates of TLR for
each bifurcation 2-stent technique were 16 of 67 (24%) after
T stenting, 9 of 32 (28%) after Culotte stenting, 4 of 15
(27%) after crush stenting, and 3 of 5 (60%) after kissing
stenting. Among 302 patients in whom the SYNTAX
score was available, the cumulative incidences of all-cause
death, cardiac death, ST, and TLR were signiﬁcantly higher
in patients with high SYNTAX scores 33 (Online
Table 3).
Discussion
In this large-scale, multicenter registry in Japan, the safety of
the SES treatment for ULMCA disease seems to be
maintained through 5 years, with the adjusted mortality rate
similar to that in patients treated for non-ULMCA disease.
At lesion-level analysis, SES implantation for non-
bifurcation ULMCA lesions was associated with excellent
5-year outcomes, with 2.4% of the TLR rate and nooccurrence of ST. In bifurcation ULMCA lesions, the
outcome of the provisional 2-stent approach was comparable
to that in the non-ULMCA lesions, whereas a higher risk
for TLR was observed in ULMCA lesions treated with the
elective 2-stent approach as compared with non-ULMCA
lesions treated similarly.
Safety of ULMCA stenting. In terms of the mortality rate
after the treatment of ULMCA disease, PCI and coronary
artery bypass grafting (CABG) have shown comparable
outcomes in randomized control trials (10) and registries
(11) for 1 to 5 years. In the current study, although no
deﬁnite conclusion can be made regarding mortality at
5 years because of a relative small number of patients with
a 5-year follow-up, there was no signiﬁcant difference in
the 5-year risk for all-cause death after adjustment for
confounders between the 2 groups of patients with or
without ULMCA stenting. Most of the fatal events in the
ULMCA group were secondary to clinical presentation at
the time of the index stent implantation and to comor-
bidities rather than to the performance of the implanted
device. Distributions of the causes of death were compa-
rable between patients with and without ULMCA treat-
ment (Online Table 2). Although ST in ULMCA lesions
might masquerade as sudden death, there was no excess of
patients who died from documented ventricular ﬁbrillation
and/or with sudden death in the ULMCA group through
5 years. The occurrence of fatal events related to stent
failure such as thrombosis or restenosis after ULMCA
stenting is rare during 5 years follow-up. However, risk
stratiﬁcation in the patient selection for ULMCA stenting
would still be required. In the subanalysis of the SYNTAX
Table 5. Unadjusted Event Rates After Index PCI According to Treatment
for ULMCA at the Lesion Level
Nonbifurcation
(n ¼ 96)
Bifurcation
Provisional
2-Stent
(n ¼ 281)
Bifurcation
Elective
2-Stent
(n ¼ 99) p Values
30 days
Total death 2 (2.0) 3 (1.1) 5 (5.1)
Cardiac death 2 (2.0) 3 (1.1) 5 (5.1)
Sudden death 0 0 1 (1.0)
MI 0 0 1 (1.1)
Stroke 0 1 (0.4) 1 (1.1)
Deﬁnite ST, patient level 0 0 1 (1.1)
Deﬁnite ST, lesion level 0 0 1 (1.1)
Deﬁnite/probable ST 1 (1.0) 0 3 (3.1)
Any ST 1 (1.0) 0 3 (3.1)
TLR, patient level 0 3 (1.1) 2 (2.1)
TLR, lesion level 0 2 (0.7) 2 (2.1)
CABG 0 1 (0.4) 0
Any revascularization 2 (2.0) 4 (1.4) 3 (3.2)
1 year
Total death 13 (13.7) 16 (13.9) 12 (12.3)
Cardiac death 9 (9.8) 11 (4.0) 10 (10.3)
Sudden death 3 (3.5) 3 (1.1) 2 (2.0)
MI 1 (1.2) 2 (0.7) 4 (4.4)
Stroke 3 (3.5) 7 (2.6) 2 (2.2)
Deﬁnite ST, patient level 0 1 (0.4) 3 (4.4)
Deﬁnite ST, lesion level 0 1 (0.4) 3 (3.4)
Deﬁnite/probable ST 1 (1.0) 1 (0.4) 6 (6.4)
Any ST 5 (5.6) 4 (1.5) 7 (7.5)
TLR, patient level 5 (5.9) 28 (10.3) 26 (28.8)
TLR, lesion level 1 (1.1) 15 (5.5) 26 (28.8)
CABG 1 (1.2) 1 (0.4) 3 (3.4)
Any revascularization 17 (19.9) 55 (20.4) 36 (40.0)
5 years
Total death 19 (23.2) 52 (22.4) 23 (25.1) 0.48
Cardiac death 11 (14.8) 23 (10.2) 14 (15.7) 0.15
Sudden death 4 (5.5) 6 (3.0) 3 (4.6) 0.23
MI 3 (5.3) 13 (6.2) 4 (4.4) 0.86
Stroke 8 (10.3) 15 (6.8) 4 (5.2) 0.48
Deﬁnite ST, patient level 0 5 (2.5) 4 (4.4) 0.11
Deﬁnite ST, lesion level 0 2 (1.2) 3 (3.4) 0.44
Deﬁnite/probable ST 1 (1.0) 5 (2.5) 6 (6.4) 0.03
Any ST 7 (7.6) 14 (7.0) 8 (9.9) 0.39
TLR, patient level 8 (10.3) 46 (19.7) 33 (38.1) <0.0001
TLR, lesion level 2 (2.4) 28 (12.1) 30 (33.5) 0.002
CABG 1 (1.2) 2 (0.8) 4 (5.2) 0.045
Any revascularization 23 (29.0) 88 (36.1) 46 (55.5) 0.001
Values are crude event n (event rates estimated by Kaplan-Meier method). *The p values are for
the comparison between the ULMCA group and non-ULMCA group at 5 years after the index
coronary intervention using the log-rank test.
Abbreviations as in Tables 1 and 2.
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662trial in the left main stratum, the mortality rate was similar
between the PCI and CABG groups. In patients with
SYNTAX scores 33, however, the cumulative incidence
of all-cause death was higher in the PCI group ascompared with that in the CABG group (10). In the
current analysis, the cumulative incidence of 5-year
mortality was markedly increased with increasing coronary
anatomic complexities as assessed by the SYNTAX score
(Online Table 3). Although treatment of left main disease
with stenting seemed to be generally safe through the
5-year period, individualized risk stratiﬁcation considering
coronary anatomic complexities would be essential when
choosing PCI as an alternative to CABG in the treatment
of ULMCA disease.
Lesion location and bifurcation stenting strategies seemed
to inﬂuence TLR outcome, but not mortality outcome
(Table 5). In the nonbifurcation ULMCA disease, the risk of
TLR and the cumulative incidence of ST tended to be lower
compared with that in the non-ULMCA group. These
favorable results were consistent with previous studies (12).
In bifurcation lesions treated with the provisional 2-stent
approach, the risk for TLR and the cumulative incidence of
ST were comparable between the ULMCA and non-
ULMCA groups. In bifurcation lesions treated with the
elective 2-stent approach, on the other hand, TLR outcome
was worse in the ULMCA group than in the non-ULMCA
group with a similar deﬁnite ST outcome. Although the
long-term outcome of TLR for the ULMCA lesion has not
yet been adequately addressed, repeated PCI for in-stent
restenosis of SES was reported to be associated with a high
rate of recurrence (13). Major improvements in stent design,
technique, and pharmacology are needed before extending
the indication for unprotected left main stenting in lesions
requiring an elective 2-stent approach. Therefore, in
selecting PCI for patients with ULMCA bifurcation lesions,
it seems crucial to predict the ultimate need for stenting
of the ostium of LCX. The very low rate of crossover from
the provisional side-branch stenting approach to the ﬁnal
2-stent approach in the current study was remarkable, sug-
gesting that experienced operators could successfully choose
those bifurcation lesions that did not need stenting of the
ostium of the LCX. The very high rate of TLR in associ-
ation with the elective 2-stent approach for the ULMCA
bifurcation lesion warrants the need for further investigation.
Study limitations. First, the present study was an observa-
tional study. Baseline differences of patient and lesion
characteristics might have biased the comparison even after
adjustment for confounders. Moreover, there were no
protocol-speciﬁed strategies for bifurcation stenting, and
selection bias at the operator level possibly inﬂuenced the
results. Secondly, because protocol-speciﬁed measurement
of myocardial biomarkers was not conducted after the index
procedures, we could not address the concerns for increased
incidence of periprocedural non–Q-wave MI in the 2-stent
group (14). Thirdly, TLR events in the present study
included both clinically driven and angiographically driven
events. Routine follow-up angiography was performed in
most of the participating centers. The clinical signiﬁcance of
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663angiographically driven TLR of the main branch as well as
the jailed side branch of ULMCA remains unclear (15). In
addition, we might have been more prone to performing
TLR for restenosis of ostial LCX than for restenosis of other
side branches, because the former usually subtends a larger
area of myocardium in jeopardy than the latter. Finally, the
SYNTAX score could not be evaluated in all the patients in
the ULMCA group.
Conclusions
The safety of ULMCA stenting relative to non-LMCA
stenting seemed to be maintained through the 5-year period.
In terms of efﬁcacy, SES implantation in nonbifurcation
ULMCA lesions was associated with an extremely low TLR
rate, whereas the elective 2-stent approach for ULMCA
lesions was associated with a markedly higher incidence of
TLR as compared with that for non-ULMCA bifurcation
lesions.
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